13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002013410
Total reported value
$750.4M
$750.4M
10 檔
77.7%
During the Q1 2026 filing period, Fcpm Iii Services B.v. (CIK: 0002013410) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $750.4M across 10 reported positions.
Fcpm Iii Services B.v. executed strategic sector rebalancing during Q1 2026, establishing 1 new positions while fully exiting 1 holdings and trimming 1 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 40.77% | -2.43% | — | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 11.66% | -0.27% | -14.98% | |
| 3 | VOR | Vor Biopharma Inc | Stock-Other | 10.17% | -0.07% | +13.82% | |
| 4 | ✓ | Engene Holdings Inc | Stock-Other | 9.08% | -6.86% | — | |
| 5 | MPLT | Maplight Therapeutics Inc | Stock-Other | 9.08% | +6.33% | — | |
| 6 | DMRA | Damora Therapeutics Inc | Stock-Other | 8.75% | -0.29% | — | |
| 7 | ✓ | Crescent Biopharma Inc. | Stock-Other | 4.27% | -0.25% | — | |
| 8 | REPL | Replimune Group Inc | Stock-Other | 2.97% | +1.17% | — | |
| 9 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 2.23% | -0.27% | — | |
| 10 | ✓ | Engene Holdings Inc | Stock-Other | 1.01% | -0.90% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VOR | Vor Biopharma Inc | +4% | +13.82% | Add |
| 2 | ✓ | Crescent Biopharma Inc. | +1.7% | — | Unchanged |
| 3 | MPLT | Maplight Therapeutics Inc | +1.7% | — | Unchanged |
| 4 | ✓ | Engene Holdings Inc | -0.1% | — | Unchanged |
| 5 | REPL | Replimune Group Inc | -0.6% | — | Unchanged |
| 6 | BCYC | Bicycle Therapeutics Plc-adr | -1% | — | Unchanged |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | -1.5% | — | Unchanged |
| 8 | ✓ | Engene Holdings Inc | -2.3% | — | Unchanged |
| 9 | DYN | Dyne Therapeutics Inc | -2.4% | -14.98% | Trim |
| 10 | DMRA | Damora Therapeutics Inc | — | NEW | New buy |
| 11 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Fcpm Iii Services B.v. reported a total U.S. public equity portfolio value of $750.4M across 10 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NAMS, DYN, VOR) accounted for 77.7% of total reported equity market value during Q1 2026.
Top New Position Initiated
DMRA
市值: $63.2M
Top Position Liquidated / Trimmed
RAPT
前期市值: $62.1M
During Q1 2026, Fcpm Iii Services B.v.'s top holdings by market value included NAMS (40.8%)、DYN (11.7%)、VOR (10.2%). The largest single position, NAMS, represented 40.8% of total portfolio value.
In Q1 2026, Fcpm Iii Services B.v. made 4 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.